Apimeds Pharmaceuticals US (APUS) Research & Development (2025)

Apimeds Pharmaceuticals US (APUS) posted Research & Development of $361104.0 for Q4 2025, down 41.73% on a QoQ basis from $619693.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Research & Development (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Research & Development history runs 1 years deep, the most recent figure standing at $361104.0 for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	696.00 Mn
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	180.00 Mn
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	7.37 Bn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	138.20 Mn
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	248.60 Mn
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	296.20 Mn
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	97.00 Mn
10	Apimeds Pharmaceuticals US	61.48 Mn	61.48 Mn	-	361,104.00

Download Data